AstraZeneca (AZN) Price & Analysis

Compare

786 Followers

AZN Stock Chart & Stats

Day’s Range― - ―

52-Week Range9,573.51p - 12,256.00p

Previous CloseN/A

Volume91.53K

Average Volume (3M)1.87M

Market Cap

£170.53B

Enterprise Value176.61B

Total Cash (Recent Filing)£7.11B

Total Debt (Recent Filing)£32.84B

Price to Earnings (P/E)26.6

Beta1.04

Next Earnings

Nov 06, 2025

EPS Estimate

1.7

Last Dividend Ex-Date

Aug 07, 2025

Dividend Yield1.91%

Share Statistics

EPS (TTM)1.60

Shares Outstanding1,550,693,000

10 Day Avg. Volume2,298,071

30 Day Avg. Volume1,873,628

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£13,789.42

Price Target Upside25.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Pipeline StrengthAnalysts reiterate a BUY rating due to a strong pipeline that reduces mid-term risks.

Sales GrowthThe valuation looks attractive, with a mid-term guide implying high single-digit sales growth and supporting a rerating to a higher price-to-earnings ratio.

Trial ResultsThere is confidence in the AVANZAR trial results based on encouraging response rates and positive data from previous studies.

Bears Say

Drug Growth IssuesMain downsides to the 2031 group EBITA include potential growth issues with the Enhertu drug and the removal of Datroway from the model.

AstraZeneca News

AstraZeneca announces results from interim analysis of DESTINY-Breast 05

Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU demonstrated a...

54m ago

AZN

DESTINY-Breast05 phase 3 trial delivers positive topline results

Positive topline results from a planned interim analysis of the DESTINY-Breast05 phase 3 trial showed ENHERTU demonstrated a...

2h ago

AZN

AstraZeneca to harmonize global listing structure

AstraZeneca (AZN) plans to harmonize its share listing structure to deliver a global listing for global investors in...

2h ago

AZN

Trump Weekly: President threatens new tariffs, announces TikTok deal

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

3d ago

Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz

The major averages were mixed near noon, with the Dow and S&P 500 edging higher following recent declines...

3d ago

AstraZeneca launches AstraZeneca Direct

AstraZeneca (AZN) announced the launch of AstraZeneca Direct, an online platform designed to create a way for eligible...

3d ago

AZN

Tempus AI price target raised to $95 from $80 at Guggenheim

Guggenheim raised the firm’s price target on Tempus AI (TEM) to $95 from $80 and keeps a Buy...

3d ago

AZN

TEM

Trump announcement gives big pharma ‘light at end of the tunnel,’ says Jefferies

After President Trump announced in a Truth Social post that he will impose an 100% tariff on any...

3d ago

AZN

BMY

Trump to impose 100% tariff on drugs unless manufacturer building U.S. plant

In a post on Truth Social, President Trump stated: “Starting October 1st, 2025, we will be imposing a...

3d ago

AZN

BMY

Monopar Therapeutics price target raised to $104 from $87 at BTIG

BTIG raised the firm’s price target on Monopar Therapeutics (MNPR) to $104 from $87 and keeps a Buy...

5d ago

AZN

MNPR

AstraZeneca’s Enhertu Shows Promise in Phase III Breast Cancer Trial

AstraZeneca ( ($GB:AZN) ) just unveiled an update. AstraZeneca, in collaboration with Daiichi Sankyo, announced positive results from...

6h ago

AstraZeneca Announces Global Harmonization of Share Listings

AstraZeneca ( ($GB:AZN) ) has provided an announcement. AstraZeneca has announced plans to harmonize its share listing structure...

6h ago

AstraZeneca Director Acquires Shares Through Dividend Reinvestment

AstraZeneca ( ($GB:AZN) ) has issued an update. AstraZeneca announced that Karen Knudsen, a Non-Executive Director, acquired 9...

4d ago

AstraZeneca’s Koselugo Gains EU Approval Recommendation for Adult Neurofibromatosis Treatment

AstraZeneca ( ($GB:AZN) ) has provided an update. AstraZeneca’s Koselugo (selumetinib), an oral MEK inhibitor, has been recommended...

7d ago

AZN FAQ

What was AstraZeneca PLC’s price range in the past 12 months?

AstraZeneca PLC lowest share price was 9573.50p and its highest was 12256.00p in the past 12 months.

What is AstraZeneca PLC’s market cap?

AstraZeneca PLC’s market cap is £170.53B.

When is AstraZeneca PLC’s upcoming earnings report date?

AstraZeneca PLC’s upcoming earnings report date is Nov 06, 2025 which is in 38 days.

How were AstraZeneca PLC’s earnings last quarter?

AstraZeneca PLC released its earnings results on Jul 29, 2025. The company reported 1.601p earnings per share for the quarter, beating the consensus estimate of 1.593p by 0.007p.

Is AstraZeneca PLC overvalued?

According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AstraZeneca PLC pay dividends?

AstraZeneca PLC pays a Semiannually dividend of 76.7p which represents an annual dividend yield of 1.91%. See more information on AstraZeneca PLC dividends here

What is AstraZeneca PLC’s EPS estimate?

AstraZeneca PLC’s EPS estimate is 1.7.

How many shares outstanding does AstraZeneca PLC have?

AstraZeneca PLC has 1,550,693,000 shares outstanding.

What happened to AstraZeneca PLC’s price movement after its last earnings report?

AstraZeneca PLC reported an EPS of 1.601p in its last earnings report, beating expectations of 1.593p. Following the earnings report the stock price went up 3.411%.

Which hedge fund is a major shareholder of AstraZeneca PLC?

Currently, no hedge funds are holding shares in GB:AZN

AstraZeneca Stock Smart Score

Outperform

Fundamentals

Return on Equity

20.09%

Trailing 12-Months

Asset Growth

-0.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AstraZeneca PLC

AstraZeneca (AZN) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Headquartered in Cambridge, UK, the company operates in various therapeutic areas including oncology, cardiovascular, renal, metabolism, respiratory, and immunology. AstraZeneca is known for its innovative drug pipeline and significant contributions to the treatment of diseases such as cancer, diabetes, and respiratory conditions. Its portfolio includes well-established products as well as new therapies that leverage cutting-edge research and development.

AstraZeneca (AZN) Earnings & Revenues

Historic Earnings Reports

AZN Stock 12 Month Forecast

Average Price Target

13,789.42p

▲(25.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10245":"10,245p","12184":"12,184p","14123":"14,123p","16062":"16,062p","18001":"18,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13789.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10245,12184,14123,16062,18001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11850,12323.076923076924,12796.153846153846,13269.23076923077,13742.307692307691,14215.384615384615,14688.461538461539,15161.538461538461,15634.615384615385,16107.692307692309,16580.76923076923,17053.846153846156,17526.923076923078,{"y":18000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11850,11999.186153846154,12148.372307692307,12297.558461538461,12446.744615384616,12595.930769230768,12745.116923076923,12894.303076923077,13043.489230769232,13192.675384615384,13341.861538461539,13491.047692307693,13640.233846153846,{"y":13789.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11850,11776.923076923076,11703.846153846154,11630.76923076923,11557.692307692309,11484.615384615385,11411.538461538461,11338.461538461539,11265.384615384615,11192.307692307691,11119.23076923077,11046.153846153846,10973.076923076924,{"y":10900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12994.64,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11549.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10788.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10330.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10246.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11103.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11884.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11287.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10534.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10500.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10329.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11026.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11850,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >